RBC Capital Remains a Buy on Repligen (RGEN)
Complete. Here is the key summaryRBC Capital analyst Dan Leonard maintained a Buy rating on Repligen (RGEN) with a $160 price target. Shares closed at $140.09. The broader market consensus is Strong Buy, with an average target of $165.36, implying 18% upside. Barclays also recently issued a Buy rating with a $160 target.
In a report released on July 22, Dan Leonard from RBC Capital maintained a Buy rating on Repligen, with a price target of $160.00. The company’s shares closed yesterday at $140.09.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Leonard is a 5-star analyst with an average return of 12.9% and a 59.12% success rate. Leonard covers the Healthcare sector, focusing on stocks such as Danaher, Repligen, and Bio-Techne.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repligen with a $165.36 average price target, implying a 18.04% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $160.00 price target.